

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS**

This statement is made at the request of The Stock Exchange of Hong Kong Limited.

The board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) has noted today’s increase in the price and trading volume of the shares of the Company and wish to state that we are not aware of any reason for such increases.

The Company was informed that a director of the Company has acquired 130,000 shares of the Company in the market today.

Save for the above, the Board confirms that there are no negotiations or agreements relating to intended acquisitions or realisations which are discloseable under rule 13.23 of the Listing Rules, neither is the Board aware of any matter discloseable under the general obligation imposed by rule 13.09 of the Listing Rules, which is or may be of a price-sensitive nature.

Made by the order of the Board of the Company, the directors of which individually and jointly accept responsibility for the accuracy of this statement.

By Order of the Board of  
**The United Laboratories  
International Holdings Limited**  
Leung Wing Hon  
*Company Secretary*

Hong Kong, 6 February 2009

*As at the date of this announcement, the Board comprises Mr Choy Kam Lok, Ms Peng Wei and Mr Leung Wing Hon as executive directors; Ms Choy Siu Chit as non-executive director; and Messrs Heng Kwo Seng, Huang Bao Guang and Song Ming as independent non-executive directors.*